Navigation Links
Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results
Date:11/6/2009

HOUSTON, Nov. 6 /PRNewswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CYBX) today announced that the company will report financial results for the second quarter ended October 23, 2009 of its fiscal year ending April 30, 2010 on Wednesday, November 18, 2009 at 5:00 PM EST. The company will conduct a conference call to discuss those results on Thursday, November 19, 2009 at 9:00 AM EST.

Fiscal Year 2010 Second Quarter Results Conference Call Instructions

To listen to the conference call live by telephone dial 877-313-8035 (if dialing from within the U.S.) or 706-679-4838 (if dialing from outside the U.S.). The conference ID is 40115998. Presentation slides will be available on-line at www.cyberonics.com no later than 8:00 AM EST on Thursday, November 19, 2009. A replay of the conference call will be available approximately two hours after the completion of the conference call by dialing 800-642-1687 (if dialing from within the U.S.) or 706-645-9291 (if dialing from outside the U.S.). The replay conference ID access code is 40115998. The replay will be available for one week on the above number and subsequently on the company's website for a period of six months.

About Cyberonics, Inc. and VNS Therapy(TM)

Cyberonics, Inc. (NASDAQ:CYBX) is a medical technology company with core expertise in neuromodulation. The company developed and markets the Vagus Nerve Stimulation (VNS) Therapy(TM) System, which is FDA-approved for the treatments of epilepsy and treatment-resistant depression. The VNS Therapy System uses a surgically implanted medical device that delivers electrical pulsed signals to the vagus nerve. Cyberonics markets the VNS Therapy System in selected markets worldwide.

Additional information on Cyberoni
'/>"/>

SOURCE Cyberonics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Cyberonics Provides Update on Depression Post-Approval Study
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Pa.,Nov.25/PRNewswire/--BioTrendsResearchGroup,Inc... report,thefirstinamulti-phasesyndicatedmarketrese...h,sStelara,fromproductlaunchthroughthefirstsixmont...tativeinformationfrom75uniqueDermatologistsandqual...trialanduseofStelara,obstaclestouse,typicalpatient...
(Date:11/25/2009)...EPARK,Md.,Nov.25/PRNewswire-USNewswire/--RemediumT...kefoamthatstopsseverebleeding,wonfirstprizeand$10,...alSecurityChallenge2009,companyofficialsannounceto...dtheworld,Remedium,steampitchedtheirinventionatthe...Business. ,, Remedium( www.remediumtechnologies...
(Date:11/25/2009)...,China,Nov.25/PRNewswire-Asia-FirstCall/--ChinaSky...")(Nasdaq: CSKI ),a,leadingfullyintegratedpharmace...erdrugsinthePeople,sRepublicofChina("PRC"),today,a...onalInstitutefor,theControlofPharmaceuticalandBiol...roducts:itsDiagnosticKitforHumanProstateSpecific,A...
Breaking Medicine Technology:Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 2Remedium Technologies Wins Most Promising Security Idea at Global Security Challenge 2009 with Blood-Clotting Foam 3China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 2China Sky One Medical, Inc. Achieved Progress in the Development of Two New Biological Testing Kits 3Duane Reade Holdings Inc Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and S 52706 1Duane Reade Holdings Inc Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and S 52706 2Duane Reade Holdings Inc Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and S 52706 3Duane Reade Holdings Inc Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and S 52706 4Duane Reade Holdings Inc Amends Terms and Extends Deadlines for Previously Announced Cash Tender Offers for Senior Secured Floating Rate Notes and S 52706 5Coming Soon Stem Cell Surgical Thread 3F 52701 1Coming Soon Stem Cell Surgical Thread 3F 52701 2Empire BlueCross BlueShield and Stony Brook University Hospital Reach New Multi year Agreement 52698 1
...New Benchmark on MRSA,in Healthcare Facilities, WA... The,following was released today by APIC: , , ...lence of Methicillin-resistant, Staphylococ... organism, in U.S. healthcare facilities.,...tly exceed previous estimates, and will for...
...se of Anacor,s,Boron-Based Chemistry in Developing...PRNewswire/ -- Anacor,Pharmaceuticals, a privately... the journal Science will publish results of resea...inical candidate,kills fungal cells by interferin...r fungal growth. This unique mechanism of,action, ...
Other Medicine Technology:Nationwide MRSA Prevalence Study to Demonstrate Full Scope of,'Superbug' Threat Facing U.S. Healthcare Facilities and Patients 2Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 2Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,AN2690; Findings Published in Science 3
(Date:11/25/2009)...tically significant survival benefit from adjuvant...(ER)-positive tumors had high levels of phosphoryl..., according to a brief communication published onl...ncer Institute . , Approximately 50% of breast c...studies have shown that ER-alpha S118-P is require...
(Date:11/25/2009)...rthritis, could help newly diagnosed diabetics, st...Day News) -- A drug commonly used to treat non-Hod...shows some promise in helping patients newly diagn...b (Rituxan), helped patients keep producing some o...estroyed some of their pancreatic beta cells, whic...
(Date:11/25/2009)...trouble with the H1N1 vaccine, , , WEDN...1 swine flu pandemic may be driving a recent spike... U.S. health official said Wednesday. , "We are...ions around the country," Dr. Anne Schuchat, direc...spiratory Diseases at the U.S. Centers for Disease...
(Date:11/25/2009)...d into the body on a carefully engineered, fingern...minate tumors in mammals, scientists report this w... . , The new approach, pioneered by bioengineers...stic disks impregnated with tumor-specific antigen...mmalian immune system to attack tumors. The new pa...
(Date:11/25/2009)...ed parts of speech colored perception of sounds ,... People can "hear" not only with their ears, but a...act, sensations on the skin designed to mimic cert...r sounds better, the Canadian scientists found. ,...ld use tactile information in this way," said Brya...
Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 2Health News:Swine Flu Tied to Rise in Pneumonias Among Young 3Health News:Swine Flu Tied to Rise in Pneumonias Among Young 4Health News:Implant-based cancer vaccine is first to eliminate tumors in mice 2Health News:Your Skin Can Help Your Ears Listen 2Health News:Your Skin Can Help Your Ears Listen 3
...inc supplements reduced the risk of death among ch... This clinical trial was conducted by researchers ...owever, the researchers did not find any significa... of the most plentiful trace elements in the body,...
...sphere this year has been the warmest since record...global warming//. The National Oceanic and Atm...ency, said the combined global land and ocean surf...rd warmer temperatures, as well as a moderate El N...
...a child’s race may be a factor in determining his/...th environmental tobacco smoke (ETS). //The study ..., who are exposed to ETS, have significantly highe...such as asthma, sudden-infant death syndrome, and ...
... P Los (Public Library of Science) suggests that c... it comes to speculating// the wishes of a termina...or NIH in Baltimore stumbled upon this finding whi... the results from 16 earlier studies where surroga...
...unts for one-third of the global TB burden, with a...ected by the TB bacillus. Every year, two mil...rom it, resulting in 1,000 deaths every day. TB ki...e of 14 years. They are exposed to the disease pri...
...ower in children who wear a special kind of no-lin...onal lenses// according to a new study published i...VS). The study found that among children wit...n lenses (SVLs).Knowing parental myopia may be hel...
Other Medicine News:Health News:Zinc Supplements Enhance Immunity in Children 2Health News:Winter Warmth Breaks All Records 2Health News:Race Affects Tobacco Absorption in Children 2Health News:TB Incidence on Rise Among Children in Tamil Nadu, Maharashtra 2
... ACT introducers represent the largest line of sta...world. They are recognized as the premier hemostas...y and electrophysiology procedures including angio...ary pacing, endomyocardial biopsies, transseptal c...
EPT-1000 XP Cardiac Ablation System
Hydrodissection Cannula
Infusion Lens Loop
Medicine Products: